ライフサイエンスコーパス: ORR

1 ORR (67% vs 49%, P = .08) and complete response (CR) or

2 ORR and median PFS were similar in patients with T790M-p

3 ORR in the intention-to-treat (ITT) population was 17% (

4 ORR in the liver was improved with the addition of SIRT

5 ORR of 97% and >/=VGPR 73% were seen in patients not ref

6 ORR was 28% (nine of 32) in patients with any degree of

7 ORR was 37.5% with a complete response rate of 12.5%, me

8 ORR was 41% (7/17); 6 additional patients (35%) had stab

9 ORR was 46% (95% CI, 34 to 57) for cabozantinib versus 1

10 ORR was 6% (five of 83) for glembatumumab vedotin versus

11 ORR was 60% and was generally consistent across subgroup

12 ORR was 66% (EBd) vs 63% (Bd).

13 ORR was evaluated on the basis of PD-L1 IC expression (I

14 ORR was higher with mutations in DNMT3A and lower for SR

15 ORRs were similar in patients who did and patients who d

16 patients with follicular lymphoma (n = 149), ORR seemed higher for obinutuzumab than rituximab (44.6%

17 vating the facet- and potential-dependent 4e-ORR on Au in alkaline solutions.

18 ein we report the discovery of a dominant 4e-ORR over the whole potential range on {310} surface of A

19 Four-electron oxygen reduction reaction (4e-ORR), a key pathway in energy conversion, is preferred o

20 ere exceptionally capable to catalyze the 4e-ORR in alkaline solution, though limited within a narrow

21 alone, with both being superior in achieving ORR compared with other treatments.

22 Use of IMs did not affect ORR, although treatment-related select AEs of any grade

23 age, revealing its excellent potential as an ORR electrocatalyst in fuel cells.

24 hat high ORR (eg, statistically exceeding an ORR of 30%) is an appropriate end point for single-arm t

25 therapy following KI discontinuation with an ORR to subsequent KI at 50% and a median PFS of 11.9 mon

26 PFS varied by histology ( P < .001), and ORR was higher in patients with significant papillary (s

27 he ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference (5.53; 95% CI, -3.08 to 14.04) were withi

28 rial-level PFS hazard ratio (HR), OS HR, and ORR odds ratio were analyzed using a weighted linear reg

29 not significantly different between LRR and ORR.

30 duration of response, 8.3 vs 2.4 months; and ORR, 32% vs 15%).

31 activity of our carbon foam for both OER and ORR independently, in a three-electrode configuration, a

32 increased number of active sites for OER and ORR.

33 tu catalysts on a carbon support for OER and ORR.

34 There was no association between OS and ORR (R(2) = 0.09; 95% CI, 0 to 0.33) and OS and PFS (R(2

35 ectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n =

36 ectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n =

37 ed a significant clinical benefit in PFS and ORR over standard-of-care sunitinib as first-line therap

38 el analysis, the association between PFS and ORR was strong (R(2) = 0.89; 95% CI, 0.80 to 0.98).

39 The primary endpoint was safety and ORR.

40 alytic performance than the state of the art ORR catalyst (Pt/C) and the oxygen evolution reaction ca

41 atalytic performance to the state-of-the-art ORR catalyst (Pt/C) and OER catalyst (Ir/C).

42 achieved in relation with the graphene based ORR catalysts applicable for MFCs, still their collectiv

43 MFCs, in which the efforts on graphene based ORR catalysts are highly imperative.

44 ental strategies of competent graphene based ORR catalysts, which are not only applicable for MFCs bu

45 e research efforts devoted on graphene based ORR catalysts.

46 ows linear kinetics; characteristic of being ORR rate limited.

47 The best ORR activity is measured with the catalyst at a size of

48 erial, denoted CPM-99Fe/C, exhibits the best ORR activity, comparable to benchmark 20% Pt/C in alkali

49 The Mo-Pt3Ni/C showed the best ORR performance, with a specific activity of 10.3 mA/cm(

50 artial response with lymphocytosis, the best ORR was 96.7%.

51 An association between ORR and OS and between PFS and OS was not established, p

52 level, there is a strong association between ORR and PFS.

53 electrocatalysts with high activity for both ORR and OER reactions and their streamlined coupling pro

54 nd good electrocatalytic properties for both ORR and OER.

55 tentials similar to the counterparts of Pt/C ORR electrode and IrO2 OER electrode.

56 provide a promising avenue to develop cheap ORR catalysts from inexpensive, scalable and biological

57 For patients with CMML, ORR was higher for azacitidine plus lenalidomide versus

58 guration with the nonprecious pCNT@Fe@GL/CNF ORR electrode and Ni-Fe LDH/NiF oxygen evolution reactio

59 lus 20 mg dexamethasone twice weekly cohort (ORR = 50%).

60 Among evaluable patients, the confirmed ORR was 10%; disease control rate (DCR) was 45%, and med

61 The confirmed ORR was 23% (12 of 52), including four ongoing complete

62 In contrast, ORR pathways on single-crystalline facets of shaped nano

63 consistent with the well-known pH-dependent ORR selectivity catalyzed by graphitic carbon materials.

64 90%-96%) and ibrutinib in relapsed disease (ORR 30%-55%), the Alliance for Clinical Trials in Oncolo

65 During ORR, a peak potential at 0.433 V was recorded, which is

66 nfigurations of the jagged nanowires enhance ORR activity versus more relaxed surfaces.

67 More importantly, their enhanced ORR performances are also demonstrated by virtue of thei

68 lays a significant role in further enhancing ORR performance.

69 n of the Shoup-Szabo equation for extracting ORR mass transport parameters using thin ionomer films w

70 vity comparable to IrO2 for OER and Pt/C for ORR, respectively, along with remarkable long term stabi

71 heoretical first principles calculations for ORR and OER in PEM based systems.

72 viously shown to be excellent candidates for ORR in terms of both activity and long-term stability, f

73 etal and nitrogen doped carbon catalysts for ORR reveal a heterogeneous composition.

74 11.5 milliamperes per square centimeter for ORR (at 0.9 volts versus reversible hydrogen electrode),

75 astuzumab) and -15% to 15% with a 95% CI for ORR difference.

76 undaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15% to

77 d RuO2 as a bifunctional electrocatalyst for ORR and OER, and hold a promise as efficient air electro

78 ials' high-efficiency as electrocatalyst for ORR.

79 trode made from the same electrocatalyst for ORR.

80 arbon-based, metal-free electrocatalysts for ORR and various defects in metal oxides/selenides for OE

81 to be robust metal-free electrocatalysts for ORR in the above-mentioned energy devices.

82 mong the most efficient electrocatalysts for ORR.

83 ives to costly Pt-based electrocatalysts for ORR.

84 velopment of advanced carbon-based NPMCs for ORR in the near future.

85 ter activity and much enhanced stability for ORR and ethanol-oxidation reaction (EOR) than those of d

86 onset potential (1.43 V for OER and 1 V for ORR vs RHE) to that of IrO2 and Pt/C, respectively.

87 oped carbon material is promising metal-free ORR catalyst for fuel cells and capacitor electrode mate

88 In this group, ORR was 40%, with 27% of patients achieving >/=VGPR.

89 ligible trials were identified; 542 arms had ORR data available for 294 regimens.

90 ast, nanoframes which exhibit extremely high ORR activity simultaneously demonstrate more significant

91 Pt (110) facets of the nanoplates have high ORR specific and mass activities that reach 7.8 milliamp

92 For single-agent regimens, high ORR was associated with regulatory approval; this relati

93 Our data suggest that high ORR (eg, statistically exceeding an ORR of 30%) is an ap

94 This work demonstrates that the high ORR activity of the Pt3Ni hollow nanoframes depends on s

95 ients with high BCL2 expression had a higher ORR (94% [17/18]) than patients with low BCL2 expression

96 ependent review panel that measured a higher ORR for obinutuzumab (44.6% v 26.7%; P = .01).

97 treated patients showed significantly higher ORR (72% v 55%; P = .0038), longer time to first dose re

98 ivity, where a approximately 25 times higher ORR activity than for commercial Pt/C (2.7 A mgPt(-1) at

99 BRAF/MEK was associated with higher ORR (OR, 2.00; 95% CrI, 1.64-2.45) compared with BRAF al

100 AEs of any grade were associated with higher ORR, but no progression-free survival benefit.

101 (DFT) calculations reveal that the improved ORR activity on the PdCuM NPs stems from the catalytical

102 The primary phase II end point was improved ORR.

103 The difference in ORR selectivity for H2O vs H2O2 depends on the thermodyn

104 accompanied by a significant enhancement in ORR activity.

105 alysts, respectively, and are also stable in ORR conditions, making them among the most efficient ele

106 onto the Mn-graphene nanocomposite increased ORR performance significantly, with a peak potential shi

107 t OV exhibited the highest diffusion-limited ORR current (5.5 mA cm(-2) ) among a series of lambda-Mn

108 the faradaic efficiencies reported for many ORR catalytic systems.

109 Maximum ORR and mean ORR were significantly associated with regu

110 Cu nanoparticles produce the maximum ORR rate under these conditions.

111 1 cancer type, the mean ORR and the maximum ORR statistically exceeded were calculated, and their as

112 Maximum ORR and mean ORR were significantly associated with regulatory approv

113 nation of agents for 1 cancer type, the mean ORR and the maximum ORR statistically exceeded were calc

114 rmation process through correlating measured ORR activity with the change of chemical bonds in precur

115 ute for the development of nonprecious metal ORR catalysts from stable metalloporphyrinic MOFs.

116 results from supported and soluble molecular ORR electrocatalysts must be interpreted with caution, a

117 HR (R2 = 0.19; 95% CI, 0.03-0.49) or 6-month ORR and OS HR (R2 = 0.05; 95% CI, 0.0001-0.31).

118 ths and OS HR but not 9-month PFS or 6-month ORR milestones and OS HR.

119 long-term durability of the bifunctional OER/ORR electrocatalyst.

120 s application to the mechanistic analysis of ORR.

121 f S(2-) and showed insignificant decrease of ORR activity for the Fe-AAPyr.

122 The recent development of ORR electrocatalysts with novel structures and compositi

123 ol experiments show that such enhancement of ORR by the AuNC is specific to nanoclusters and not to p

124 Evaluation of ORR thresholds between 20% and 60% as potential trial en

125 vity, strategies behind the modifications of ORR catalysts and update the research efforts devoted on

126 review is to outline the significant role of ORR catalysts, factors influencing the ORR activity, str

127 d experimental results on the selectivity of ORR catalyzed by these materials.

128 ed NSCLC with a large magnitude of effect on ORR may have a large PFS effect.

129 ogic outcomes of laparoscopic (LRR) vs open (ORR) rectal resection for rectal cancer.

130 etastatic uLMS failed to improve PFS, OS, or ORR.

131 positive for T790M who had better outcomes (ORR, 69%; PFS, 16.5 months) as well as a subset of patie

132 ative plasma had overall favorable outcomes (ORR, 46%; median PFS, 8.2 months), tumor genotyping dist

133 ients negative for T790M with poor outcomes (ORR, 25%; PFS, 2.8 months).

134 he oxygen dissociation step from the overall ORR.

135 In 60 evaluable patients, ORR was 48% (95% confidence interval [CI], 35-62).

136 ilar in patients with T790M-positive plasma (ORR, 63%; PFS, 9.7 months) or T790M-positive tumor (ORR,

137 ved 90% enhancement or 40% suppression in Pt ORR activity under compression or tension, respectively,

138 R) in four patients [(overall response rate (ORR) = 9%, 95% confidence interval [CI] 3% to 22%)].

139 tion of response, and overall response rate (ORR) according to the presence of del(17p) compared with

140 objectives included objective response rate (ORR) and 24-week progression-free survival (PFS) rate; o

141 Overall response rate (ORR) and minimal residual disease (MRD) by next-generati

142 ry endpoints included overall response rate (ORR) and overall survival (OS).

143 Objective response rate (ORR) and progression-free survival (PFS) were analyzed i

144 dds ratios (OR) for objective response rate (ORR) and serious adverse events.

145 ew committee-assessed overall response rate (ORR) by 2007 International Working Group criteria.

146 y outcome was week 24 overall response rate (ORR) defined as complete or partial response.

147 Objective response rate (ORR) is an increasingly important end point for accelera

148 st efficacy with an objective response rate (ORR) of 4% and clinical benefit rate of 21%.

149 itor, demonstrated an overall response rate (ORR) of 60% in advSM but biomarkers predictive of respon

150 e was to evaluate the overall response rate (ORR) of CMP.

151 uate the safety and objective response rate (ORR) of imiquimod in combination with systemic albumin b

152 Overall response rate (ORR) to first KI was 62% (complete response 14%).

153 r BV plus DTIC, the objective response rate (ORR) was 100% and the complete remission (CR) rate was 6

154 The overall response rate (ORR) was 21% (14/66), and 15% achieved very good partial

155 uable population, the overall response rate (ORR) was 56% (29/52) and was similar between the 10 mg/k

156 The overall response rate (ORR) was 67% (44/66); 42% achieved very good partial res

157 The objective response rate (ORR) was 92%, with 73% achieving complete remission.

158 or number of doses, objective response rate (ORR) was significantly higher in patients who experience

159 erall survival, and objective response rate (ORR) were 11.0 months, 18.5 months, and 29%, respectivel

160 survival (OS), and objective response rate (ORR) were assessed according to tumor location and treat

161 survival (OS), and objective response rate (ORR) were assessed according to tumor location and treat

162 s were calculated for overall response rate (ORR) within 6 months, 9-month progression-free survival

163 y end points included overall response rate (ORR), duration of response (DOR), progression-free survi

164 Objective response rate (ORR), overall survival, and safety were secondary end po

165 t was composite CNS objective response rate (ORR), requiring all of the following: >/= 50% reduction

166 verall survival (OS), overall response rate (ORR), response duration (RD), time to treatment failure

167 primary end point was overall response rate (ORR).

168 primary end point was overall response rate (ORR).

169 primary end point was overall response rate (ORR).

170 e primary outcome was overall response rate (ORR).

171 nts were safety and objective response rate (ORR).

172 int was safety, and objective response rate (ORR, confirmed) was a key secondary end point.

173 were evaluable for objective response rate (ORR; 15%; 95% CI, 7% to 26%).

174 is is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%).

175 follicular lymphoma (overall response rate [ORR] 90%-96%) and ibrutinib in relapsed disease (ORR 30%

176 Objective response rates (ORRs) at any site were similar (68.1% v 76.4% in control

177 tat produce superior overall response rates (ORRs) to azacitidine is not known.

178 ction was significant (ratio of odds ratios [ORR] 1.96, 95% CI 1.11-3.46; p=0.02).

179 eduction reaction/oxygen evolution reaction (ORR/OER) catalytic activities of p-orbital heteroatom-do

180 specific and mass oxygen reduction reaction (ORR) activities with improvement factors of 51.1 and 34.

181 ecessary to boost oxygen reduction reaction (ORR) activity in core/shell M/platinum (Pt) catalysts (w

182 and a comparable oxygen reduction reaction (ORR) activity to that of Pt/C as well as a better stabil

183 of Pt during the oxygen reduction reaction (ORR) affects the performance and economic viability of f

184 ytic site for the oxygen reduction reaction (ORR) and (ii) demonstration of competitive PEFC performa

185 stability for the oxygen-reduction reaction (ORR) and liquid fuel oxidation reaction is very importan

186 catalysts for the oxygen reduction reaction (ORR) and other electrocatalytic processes requires detai

187 The oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) are cornerstone

188 catalysts for the oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) in fuel cells o

189 catalysts for the oxygen-reduction reaction (ORR) and oxygen-evolution reaction (OER) is critical for

190 is, including the oxygen-reduction reaction (ORR) and oxygen-evolution reaction (OER), is a critical

191 taneously for the oxygen reduction reaction (ORR) and the oxygen evolution reaction (OER) is currentl

192 ns (OH(-)) by the oxygen reduction reaction (ORR) at a diffusion-controlled rate in aerated phosphate

193 l modification of oxygen reduction reaction (ORR) catalysts to improve the maximum volumetric power d

194 as precursors for oxygen reduction reaction (ORR) catalysts.

195 irst study of the oxygen reduction reaction (ORR) catalyzed by a cofacial porphyrin scaffold accessed

196 c activity toward oxygen reduction reaction (ORR) compared to Pt/C catalyst in both alkaline and acid

197 ctrocatalysis for oxygen reduction reaction (ORR) for proton exchange membrane fuel cells (PEMFCs) ar

198 w kinetics of the oxygen reduction reaction (ORR) impede the widespread uptake of low-temperature fue

199 materials for the oxygen reduction reaction (ORR) in acidic media, which is crucial for large-scale d

200 a reactant in the oxygen reduction reaction (ORR) in alkaline media, an adequate supply of water is r

201 s very active for oxygen reduction reaction (ORR) in alkaline media.

202 for the cathodic oxygen reduction reaction (ORR) in microbial fuel cells (MFCs).

203 ctro-catalyst for oxygen reduction reaction (ORR) in proton exchange membrane (PEM) fuel cells, oxyge

204 tive site for the oxygen reduction reaction (ORR) is different under acidic and alkaline conditions.

205 efficiency of the oxygen reduction reaction (ORR) is furnished from a systematic electrochemical stud

206 The oxygen reduction reaction (ORR) is of great importance for various renewable energy

207 athode towards an oxygen reduction reaction (ORR) is one of the high-priority research directions for

208 work reports the oxygen reduction reaction (ORR) kinetics of metal nanoparticle catalysts between 50

209 of the multi-step oxygen reduction reaction (ORR) makes it difficult to investigate the oxygen dissoc

210 We find that the oxygen-reduction reaction (ORR) on CNTs initially produces LiO2, which subsequently

211 s results for the oxygen reduction reaction (ORR) on Pt UME-NPEs in 0.1 M H2SO4 are also shown.

212 esulting from the oxygen reduction reaction (ORR) or hydrogen peroxide reduction on platinum, has bee

213 activity for the oxygen reduction reaction (ORR) requires optimization of both the specific activity

214 Here, the oxygen reduction reaction (ORR) was studied under proton diffusion-limited conditio

215 that facilitates the O2 reduction reaction (ORR), a PCET process important in fuel cells and O2 redu

216 c activity in the oxygen reduction reaction (ORR), as evidenced by an onset potential of +0.97 V, exc

217 rsion through the oxygen reduction reaction (ORR), carbon-based metal-free catalysts have also been d

218 EMFC), namely the oxygen reduction reaction (ORR), necessitates an accurate and detailed structural u

219 ctivities for the oxygen reduction reaction (ORR), oxygen evolution reaction (OER), and hydrogen evol

220 actions including oxygen reduction reaction (ORR), oxygen evolution reaction (OER), and hydrogen evol

221 as a support for oxygen reduction reaction (ORR)-active ordered intermetallic Fe3 Pt NPs.

222 catalysts for the oxygen reduction reaction (ORR).

223 activity for the oxygen reduction reaction (ORR).

224 ocatalyst for the oxygen reduction reaction (ORR).

225 ocatalyst for the oxygen reduction reaction (ORR).

226 the two-electron oxygen reduction reaction (ORR); however, the chemical potential of H2 replaces an

227 molecular oxygen (oxygen reduction reaction, ORR), which makes them fuel-cell cathode catalysts with

228 he oxygen reduction and evolution reactions (ORR and OER) are vital for the performances of rechargea

229 or oxygen reduction and evolution reactions (ORR and OER) in energy conversion devices.

230 trocatalysts for oxygen reduction reactions (ORR) in fuel cells.

231 w the contributions of the oxygen reduction (ORR) and the oxygen evolution (OER) half-reactions on th

232 tic search was used to identify the reported ORR for each eligible treatment arm that had been presen

233 atomic Fe catalyst has achieved respectable ORR activity in challenging acidic media (0.5 M H2SO4),

234 Respective ORRs were 20%, 22%, and 20%.

235 R activity) and Pt/C (92 % vs. 78 % retained ORR activity after 10 h running) in alkaline electrolyte

236 of the polydopamine-coated material revealed ORR occurring via 4.14 and 4.00 electrons, respectively.

237 Secondary end point revealed ORR of 12% (10 of 83) versus 12% (five of 41) overall, a

238 Moreover, the reversible ORR/OER activity trend for a wide variety of M-C3N4 comp

239 Unplanned analysis showed ORR of 18% (five of 28) versus 0% (0 of 11) in patients

240 h azacitidine-based combinations had similar ORR to azacitidine monotherapy, although patients with C

241 ombination of PomCyDex results in a superior ORR and PFS compared with PomDex in patients with lenali

242 ted with polydopamine, resulting in superior ORR activity compared to the uncoated PDA structures.

243 potential trial end points demonstrated that ORR statistically exceeding 30% with a single agent had

244 The ORR activity of the material was further improved by int

245 The ORR activity versus the bulk lattice parameter follows a

246 The ORR activity was investigated using chemical and electro

247 The ORR for G-FC was 62% (13/21), with 10% CR and 14% CRi, i

248 The ORR for patients with Fuhrman grade 4 and/or sarcomatoid

249 The ORR for the entire cohort was 95%, and the 12-month prog

250 The ORR rates of Ag, Au, Cu, Ni, Pd, Rh and Pt measured at 6

251 The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference

252 The ORR was 100% in patients with del(17p)/TP53 mutations an

253 The ORR was 31.0% (95% CI, 17.6 to 47.1) in 42 response-eval

254 The ORR was 32.6%, and the median DOR was 7.4 months.

255 The ORR was 38.9% (95% confidence interval [CI], 23-54.8%) a

256 The ORR was 52% in 42 evaluable lenalidomide-refractory pati

257 The ORR was 67% (23% complete response), with a median durat

258 ment of electrocatalysts for the OER and the ORR is of essential importance.

259 For BV plus bendamustine, the ORR was 100% and the CR rate was 88%.

260 When catalyzing the ORR, FeNx Cy moieties are more selective than Fe particl

261 In contrast, the ORR activity is mostly unaffected by the ligand chemistr

262 carfilzomib plus low-dose dexamethasone, the ORR was 55% with a safety profile comparable to that of

263 polarized sufficiently negative to drive the ORR or H2O2 reduction on the platinum surface, mainly us

264 The nanoporous Pt surface formed during the ORR was visualized by AFM and high-resolution SEM, which

265 at moderately negative potentials during the ORR.

266 is then applied to successfully explain the ORR/OER activities of other transition-metal spinels, in

267 to that of precious metal benchmarks for the ORR and OER in alkaline media.

268 electrocatalysts have been designed for the ORR or the OER; however, the origin of the advanced acti

269 ontributes to the excellent activity for the ORR.

270 its excellent activity and stability for the ORR/OER in alkaline media.

271 dral site is the activity descriptor for the ORR/OER of spinels, consolidating the role of electron o

272 These radicals are produced from the ORR byproduct, hydrogen peroxide, through a 1 electron r

273 of transferred electrons (n) involved in the ORR was >3.8, indicating a dominant quasi-4-electron pat

274 the addition of dexamethasone increased the ORR with all responses of >/=partial response occurring

275 le of ORR catalysts, factors influencing the ORR activity, strategies behind the modifications of ORR

276 up of 23 months (range, 1 to 43 months), the ORR was 38% for patients receiving azacitidine, 49% for

277 y-evaluable patients treated at the MTD, the ORR was 90%.

278 An in-depth investigation of the ORR in acid reveals a behavior which is similar to that

279 old surfaces exhibit high sensitivity of the ORR pathway to its atomic structures.

280 By comparing theoretical calculations of the ORR selectivity at a well-defined graphene nanostructure

281 Here, a descriptor study on the ORR/OER of spinel oxides is presented.

282 e prior therapies (range, two to seven), the ORR was 19%; median response duration, 6.0 months (95% C

283 en applied to acidic electrolytes, shows the ORR preferring the two-electron pathway, consistent with

284 We have studied the ORR on eight platinum (Pt)-lanthanide and Pt-alkaline ea

285 the assignment of descriptors related to the ORR activity and stability.

286 omprehensive framework for understanding the ORR and PCET processes in general.

287 ate of the rate constant associated with the ORR.

288 The ORRs were 70% and 49% (P = .03) for patients treated wit

289 containing more elements which contribute to ORR activity.

290 superior electrocatalytic activities towards ORR, besides excellent stability and good methanol toler

291 utstanding electrocatalytic activity towards ORR comparable to the commercial Pt/C catalyst in neutra

292 %; PFS, 9.7 months) or T790M-positive tumor (ORR, 62%; PFS, 9.7 months) results.

293 RR and 79 (6.1%) of 1292 patients undergoing ORR (RR, 1.17; 95% CI, 0.89-1.53; P = .26; I2 = 0%) in 9

294 R and 104 (10.4%) of 998 patients undergoing ORR (RR, 1.31; 95% CI, 1.05-1.64; P = .02; I2 = 0%) in 5

295 ized clinical trials (RCTs) comparing LRR vs ORR.

296 tions in DNMT3A and lower for SRSF2, whereas ORR duration improved with fewer mutations.

297 her in patients undergoing LRR compared with ORR.

298 it, including uRCC, where it correlated with ORR (43% v 11%), median PFS (12.9 v 1.9 months), and ove

299 95, to June 30, 2016, that compared LRR with ORR for histologically proven rectal cancer in adult pat

300 In this work, ORR mass transport behavior is reported for methylated h